Zimbabwe has turned down a substantial American health deal valued at 367 million US dollars (£272m) spanning five years over the United States' demand for confidential information.
The decision was revealed following a government memo dated December was leaked, indicating that Head of State Emmerson Mnangagwa felt the arrangement was "unbalanced".
A government representative has since explained that the US was requesting genetic material for scientific study and commercial gain but was unwilling to guarantee the benefits from future treatments.
"We will now turn to the challenging and unfortunate task of winding down our health aid in Zimbabwe," stated US ambassador to Zimbabwe Pamela Tremont in a statement.
Her embassy noted the US had provided over $1.9bn for health programmes to Zimbabwe during the past twenty years.
A medical body in Zimbabwe has called for further dialogue to find a deal suitable to both sides so the nation's critical HIV programme can proceed.
Wider Context
This development comes after a comparable case in Kenya, where a high court blocked a similar health funding agreement after legal challenges were filed about the safety of citizens' health data.
After returning to office last year, US President Donald Trump has slashed foreign aid and shut down the US Agency for International Development (USAID).
USAID had managed aid for the US government, but Trump stated its expenditure was "wasteful" and his government was seeking government-to-government agreements to boost transparency and accountability.
Based on statements, 16 nations in Africa have so far signed these new agreements, constituting more than $18.3bn in committed funds.
Details of the Declined Deal
The funds for Zimbabwe was intended to supported "tackling HIV/Aids, TB, malaria, healthcare for mothers and children, and preparing for epidemics".
"It is our view this cooperation would have delivered extraordinary benefits for Zimbabwean communities, especially the 1.2 million currently receiving antiretroviral therapy via US-supported initiatives," the Ambassador commented.
However, government spokesperson Nick Mangwana argued the arrangement was "unequal".
"Our nation was requested to provide its genetic material and health information over an extended period, without any equivalent guarantee of benefiting from any medical innovations – like vaccines, diagnostics, or treatments – that could result from that provided information," Mangwana explained.
"In essence, our nation would supply the basic resources for scientific discovery with no assurance that the end products would be available to our people should a new disease outbreak emerge."
Sovereignty and Global Health
He also said that the US's withdrawal from the World Health Organization (WHO) and its pursuit of one-on-one deals were disrupting systems already set up via the global organization.
The spokesperson cited its Pandemic Benefit-Sharing scheme created to deal with future pandemics.
"This mechanism is designed to ensure that when a country provides its information, the resulting advantages – including medicines and cures – are shared equitably, not commercialised exclusively by those with the capability to develop them."
These objections over the US deal "should not be misconstrued as opposition to America," he added.
"We welcome further discussions with our US partners on how subsequent co-operation might be structured in a manner that respects the sovereignty and dignity of both nations."
Medical Community Response
Medical experts said it recognised the official position, but suggested that talks need to persist since a large portion of the country's HIV programmes relied on external financing.
"If technical issues exist, such as those relating to information security or implementation frameworks, these can often be addressed through technical clarification and negotiated safeguards," the group said.
This impasse highlights the continuing challenges between receiving much-needed foreign assistance and safeguarding a country's data in an ever more data-driven world.